Anterogen’s stem cell-based anal fistula drug gets green light from KFDA

Published: 2012-01-25 06:59:00

Updated: 2012-01-25 06:59:00

The Korea Food and Drug Administration said Thursday that it has approved Cupistem, a stem cell-based anal fistula drug by Anterogen Co., a subsidy of Bukwang Pharmaceutical Co.

Anterogen’s Cupistem is a stem cell treatment that uses a patient’s own stem cells from fatty tissue to treat anal f...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK